BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 34219326)

  • 1. Preventing recurrent preterm birth with 125 mg of 17-alpha-hydroxyprogesterone caproate.
    Fukuda T; Kyozuka H; Murata T; Yasuda S; Yamaguchi A; Fujimori K
    J Obstet Gynaecol Res; 2021 Sep; 47(9):3119-3126. PubMed ID: 34219326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gestational age at initiation of 17-alpha hydroxyprogesterone caproate and recurrent preterm birth.
    Ning A; Vladutiu CJ; Dotters-Katz SK; Goodnight WH; Manuck TA
    Am J Obstet Gynecol; 2017 Sep; 217(3):371.e1-371.e7. PubMed ID: 28526452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomised trial to compare 200 mg micronised progesterone effervescent vaginal tablet daily with 250 mg intramuscular 17 alpha hydroxy progesterone caproate weekly for prevention of recurrent preterm birth.
    Shambhavi S; Bagga R; Bansal P; Kalra J; Kumar P
    J Obstet Gynaecol; 2018 Aug; 38(6):800-806. PubMed ID: 29557230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 17-OHPC to Prevent Recurrent Preterm Birth in Singleton Gestations (PROLONG Study): A Multicenter, International, Randomized Double-Blind Trial.
    Blackwell SC; Gyamfi-Bannerman C; Biggio JR; Chauhan SP; Hughes BL; Louis JM; Manuck TA; Miller HS; Das AF; Saade GR; Nielsen P; Baker J; Yuzko OM; Reznichenko GI; Reznichenko NY; Pekarev O; Tatarova N; Gudeman J; Birch R; Jozwiakowski MJ; Duncan M; Williams L; Krop J
    Am J Perinatol; 2020 Jan; 37(2):127-136. PubMed ID: 31652479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pregnancy duration with use of 17-α-hydroxyprogesterone caproate in a retrospective cohort at high risk of recurrent preterm birth.
    Massa K; Childress K; Vricella LK; Boerrigter A; Franklin BHK; Sauer M; Armbruster R; Tomlinson T
    Am J Obstet Gynecol MFM; 2020 Nov; 2(4):100219. PubMed ID: 33345927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonresponse to 17-alpha hydroxyprogesterone caproate for recurrent spontaneous preterm birth prevention: clinical prediction and generation of a risk scoring system.
    Manuck TA; Stoddard GJ; Fry RC; Esplin MS; Varner MW
    Am J Obstet Gynecol; 2016 Nov; 215(5):622.e1-622.e8. PubMed ID: 27418444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrent Preterm Birth Reduction by 17-Hydroxyprogesterone Caproate in Dichorionic/Diamniotic Twin Gestation.
    Megli C; Combs CA; Venkataramanan R; Lemon L; Caritis SN
    Am J Perinatol; 2022 Aug; 39(11):1183-1188. PubMed ID: 33321529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
    Manuck TA; Esplin MS; Biggio J; Bukowski R; Parry S; Zhang H; Huang H; Varner MW; Andrews W; Saade G; Sadovsky Y; Reddy UM; Ilekis J;
    Am J Obstet Gynecol; 2016 Mar; 214(3):376.e1-8. PubMed ID: 26692181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaginal progesterone compared with intramuscular 17-alpha-hydroxyprogesterone caproate for prevention of recurrent preterm birth in singleton gestations: a systematic review and meta-analysis.
    Boelig RC; Locci M; Saccone G; Gragnano E; Berghella V
    Am J Obstet Gynecol MFM; 2022 Sep; 4(5):100658. PubMed ID: 35562009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of partial compliance on the prevention of recurrent preterm birth in women receiving weekly 17 alpha-hydroxyprogesterone caproate injections.
    Haidar ZA; Moussa HN; Hosseini Nasab S; Sibai BM
    J Matern Fetal Neonatal Med; 2017 Dec; 30(24):2926-2932. PubMed ID: 27921517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Possible Mechanism of Action of 17α-Hydroxyprogesterone Caproate: Enhanced IL-10 Production.
    Megli CJ; Hauspurg A; Venkataramanan R; Caritis SN
    Am J Perinatol; 2023 Oct; 40(14):1585-1589. PubMed ID: 34784615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant 17-hydroxyprogesterone caproate in women with history-indicated cerclage: A systematic review and meta-analysis.
    Eke AC; Sheffield J; Graham EM
    Acta Obstet Gynecol Scand; 2019 Feb; 98(2):139-153. PubMed ID: 30339274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaginal progesterone vs intramuscular 17-hydroxyprogesterone caproate for prevention of recurrent preterm birth: a randomized controlled trial.
    Boelig RC; Schoen CN; Frey H; Gimovsky AC; Springel E; Backley S; Berghella V
    Am J Obstet Gynecol; 2022 May; 226(5):722.e1-722.e12. PubMed ID: 35189093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progesterone therapy for prevention of recurrent spontaneous preterm birth in a minority patient population: a retrospective study.
    Mazza GR; Komatsu E; Ponzio M; Bai C; Cortessis VK; Sasso EB
    BMC Pregnancy Childbirth; 2024 Apr; 24(1):252. PubMed ID: 38589796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utilization, adherence, and outcomes of 17-alpha hydroxyprogesterone caproate for recurrent spontaneous preterm birth prevention.
    Zhang S; Rascati KL
    Curr Med Res Opin; 2021 Sep; 37(9):1667-1675. PubMed ID: 34030550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Placental histology for targeted risk assessment of recurrent spontaneous preterm birth.
    Suresh S; Freedman A; Adams M; Hirsch E; Ernst LM
    Am J Obstet Gynecol; 2024 Apr; 230(4):452.e1-452.e11. PubMed ID: 37751829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant 17-hydroxyprogesterone caproate in women withultrasound-indicated cerclage: a systematic review and meta-analysis.
    Lichter KE; Sheffield J; Graham EM; Eke AC
    J Matern Fetal Neonatal Med; 2020 Sep; 33(18):3177-3184. PubMed ID: 30626240
    [No Abstract]   [Full Text] [Related]  

  • 18. Adherence rates and outcomes for 17-hydroxyprogesterone caproate use in women with a previous history of preterm birth.
    Edwards AM; Lowry SA; Mikovich S; Forinash AB; Babbar S
    Am J Obstet Gynecol MFM; 2020 Aug; 2(3):100166. PubMed ID: 33345885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intramuscular progesterone in women with twins and a prior singleton spontaneous preterm birth.
    Ward A; Greenberg V; Valcarcel B; Boelig RC; Al-Kouatly HB; Berghella V
    Am J Obstet Gynecol MFM; 2020 Aug; 2(3):100124. PubMed ID: 33345870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progesterone receptor polymorphisms and clinical response to 17-alpha-hydroxyprogesterone caproate.
    Manuck TA; Lai Y; Meis PJ; Dombrowski MP; Sibai B; Spong CY; Rouse DJ; Durnwald CP; Caritis SN; Wapner RJ; Mercer BM; Ramin SM
    Am J Obstet Gynecol; 2011 Aug; 205(2):135.e1-9. PubMed ID: 21600550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.